| Ytd | 62.00% | |
| 1y | 191.40% |
| Open | 37.11 | Prev Close | 36.80 | Low | 37.11 | High | 39.59 | Mkt Cap | 1.85B |
| Vol | 1.09M | Avg Vol | 799.07K | EPS | -2.74 | P/E | N/A | Forward P/E | 29.95 |
| Beta | 1.62 | Short Ratio | 9.82 | Inst. Own | 100.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 29.01 | 200-d Avg | 22.75 | 1yr Est | 36.88 |
10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a
This Agreement resolves the patent litigation UroGen initiated in response to Teva's submission